Stem Cell Based Gene Therapy in Prostate Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Jae Heon | - |
dc.contributor.author | Lee, Hong Jun | - |
dc.contributor.author | Song, Yun Seob | - |
dc.date.accessioned | 2021-08-12T00:25:08Z | - |
dc.date.available | 2021-08-12T00:25:08Z | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 2314-6133 | - |
dc.identifier.issn | 2314-6141 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/13024 | - |
dc.description.abstract | Current prostate cancer treatment, especially hormone refractory cancer, may create profound iatrogenic outcomes because of the adverse effects of cytotoxic agents. Suicide gene therapy has been investigated for the substitute modality for current chemotherapy because it enables the treatment targeting the cancer cells. However the classic suicide gene therapy has several profound side effects, including immune-compromised due to viral vector. Recently, stem cells have been regarded as a new upgraded cellular vehicle or vector because of its homing effects. Suicide gene therapy using genetically engineered mesenchymal stem cells or neural stem cells has the advantage of being safe, because prodrug administration not only eliminates tumor cells but consequently kills the more resistant therapeutic stem cells as well. The attractiveness of prodrug cancer gene therapy by stem cells targeted to tumors lies in activating the prodrug directly within the tumor mass, thus avoiding systemic toxicity. Therapeutic achievements using stem cells in prostate cancer include the cytosine deaminase/5-fluorocytosine prodrug system, herpes simplex virus thymidine kinase/ganciclovir, carboxyl esterase/CPT11, and interferon-beta. The aim of this study is to review the stem cell therapy in prostate cancer including its proven mechanisms and also limitations. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Hindawi Publishing Corporation | - |
dc.title | Stem Cell Based Gene Therapy in Prostate Cancer | - |
dc.type | Article | - |
dc.publisher.location | 영국 | - |
dc.identifier.doi | 10.1155/2014/549136 | - |
dc.identifier.scopusid | 2-s2.0-84935875874 | - |
dc.identifier.wosid | 000340143000001 | - |
dc.identifier.bibliographicCitation | BioMed Research International, v.2014 | - |
dc.citation.title | BioMed Research International | - |
dc.citation.volume | 2014 | - |
dc.type.docType | Review | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Biotechnology & Applied Microbiology | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalWebOfScienceCategory | Biotechnology & Applied Microbiology | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.subject.keywordPlus | POSITRON-EMISSION-TOMOGRAPHY | - |
dc.subject.keywordPlus | URACIL PHOSPHORIBOSYLTRANSFERASE GENE | - |
dc.subject.keywordPlus | IN-VIVO | - |
dc.subject.keywordPlus | CYTOSINE DEAMINASE | - |
dc.subject.keywordPlus | STROMAL CELLS | - |
dc.subject.keywordPlus | TUMOR-GROWTH | - |
dc.subject.keywordPlus | THYMIDINE KINASE/GANCICLOVIR | - |
dc.subject.keywordPlus | TRANSGENE EXPRESSION | - |
dc.subject.keywordPlus | INDUCED APOPTOSIS | - |
dc.subject.keywordPlus | INTERFERON-BETA | - |
dc.subject.keywordAuthor | 비뇨기과학 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.